Latest news with #SteinCares
The Hindu
26-05-2025
- Business
- The Hindu
Lupin, SteinCares ink pact to roll out biosimilar for eye disease in Latin America
Drugmaker Lupin has entered into a licence and supply agreement with SteinCares for commercialisation of its biosimilar ranibizumab across Latin America, excluding Mexico and Argentina. SteinCares, which is specialty healthcare company in Latin America, will handle all regulatory filings, registrations and commercialisation of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same, under the agreement, it said on Monday. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is used in treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy and Myopic Choroidal Neovascularization, Lupin said. 'Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients,' Cyrus Karkaria, president – Biotechnology, Lupin, said in a release. Chief Strategy Officer at SteinCares Sebastian Katz said the company has consistently been the first to market products from highly regulated markets across several countries in the region. The partnership with Lupin strengthens its portfolio and reinforces SteinCares' position as a biosimilar powerhouse in Latin America.
&w=3840&q=100)
Business Standard
26-05-2025
- Business
- Business Standard
Lupin signs licensing deal with SteinCares for ranibizumab in LatAm
Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding Mexico and Argentina Anjali Singh Mumbai Pharma major Lupin has signed a licence and supply agreement with Costa Rica-based SteinCares for the commercialisation of its biosimilar ranibizumab (used to treat eye conditions) in Latin America, excluding Mexico and Argentina. As part of the agreement, SteinCares will manage regulatory filings, registrations and commercial operations in the region, while Lupin will handle manufacturing. Ranibizumab is a recombinant humanised monoclonal antibody fragment used to inhibit vascular endothelial growth factor A (VEGF-A). It is indicated for the treatment of several retinal conditions, including neovascular (wet) age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, diabetic retinopathy and myopic choroidal neovascularisation. Cyrus Karkaria, President of Biotechnology at Lupin, said the company aims to improve access to retinal therapies in Latin America through this partnership. 'Our intent is to transform retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients,' Karkaria added. Sebastian Katz, Chief Strategy Officer at SteinCares, said the deal would enhance the company's biosimilar portfolio in the region and support cost savings for healthcare systems through access to products from highly regulated markets. 'This partnership with Lupin strengthens our portfolio and position as a biosimilar powerhouse in Latin America. We have consistently been first to market products from highly regulated markets across several countries in the region,' said Katz. Lupin is headquartered in Mumbai and operates across more than 100 markets. Its portfolio includes branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients. The company operates 15 manufacturing sites and seven R&D centres globally.
Time of India
26-05-2025
- Business
- Time of India
Lupin inks licensing deal to supply biosimilar ranibizumab in Latin America
Drug maker Lupin on Monday said it has entered into a licence and supply agreement with SteinCares for commercialisation of biosimilar ranibizumab across Latin America , excluding Mexico and Argentina. Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialisation of Ranibizumab in Latin America, while Lupin will be responsible for manufacturing the same, the Mumbai-based drug maker said in a statement. Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo Also Read: Lupin partners with Honeywell for usage of propellant for inhalers "Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients," Lupin President Biotechnology Cyrus Karkaria said. Live Events Shares of Lupin were trading 0.32% down at ₹1,972.80 apiece on BSE.
Business Standard
26-05-2025
- Business
- Business Standard
Lupin enters into license and supply agreement with SteinCares
For commercialization of Lupin's biosimilar ranibizumab across Latin America Lupin has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America, for commercialization of Lupin's biosimilar ranibizumab across Latin America excluding Mexico and Argentina. Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).
Business Upturn
26-05-2025
- Business
- Business Upturn
Lupin and SteinCares sign license and supply agreement for Ranibizumab in Latin America
By Aman Shukla Published on May 26, 2025, 10:31 IST Lupin Limited has signed a license and supply agreement with SteinCares, a Latin America-based specialty healthcare company, for the commercialization of its biosimilar ranibizumab. The agreement covers all Latin American markets except Mexico and Argentina. Under the terms of the agreement, SteinCares will be responsible for regulatory filings, obtaining product registrations, and managing commercialization activities for ranibizumab across the specified LATAM region. Lupin will retain responsibility for manufacturing the biosimilar. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment. It targets and inhibits vascular endothelial growth factor A (VEGF-A), which plays a key role in the formation of abnormal blood vessels in the eye. The biosimilar is used in the treatment of several retinal disorders, including: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Macular Edema Following Retinal Vein Occlusion (RVO) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Myopic Choroidal Neovascularization (mCNV) The agreement aims to expand access to ophthalmology treatments in Latin America, leveraging SteinCares' regional presence and Lupin's biosimilar capabilities. Dr Cyrus Karkaria, President Biotechnology, Lupin stated, 'Our partnership with SteinCares underscores our commitment to providing innovative, high-quality healthcare solutions to patients in LATAM. Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients.' Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
